Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETASOL HC vs BETA-2
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
FDA-approved: Treatment of asthma (acute bronchospasm and prophylaxis), COPD exacerbations,Off-label: Preterm labor tocolysis, hyperkalemia
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Terminal elimination half-life of 3-6 hours; clinical context: requires frequent dosing (every 4-6 hours) for sustained bronchodilation.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Metabolized by catechol-O-methyltransferase (COMT), monoamine oxidase (MAO), and sulfate conjugation in the gastrointestinal tract and liver.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Primarily renal excretion of unchanged drug and sulfate conjugates; 60-70% as unchanged drug, 15-20% as sulfate metabolites, minor biliary/fecal elimination (<5%).
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
50-60% bound to albumin.
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
4-5 L/kg (large Vd indicating extensive tissue distribution, particularly lung tissue).
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
Inhalation: 10-20% (due to deposition and first-pass metabolism from swallowed portion). Oral: 40-50% (significant first-pass metabolism to sulfate conjugates).
No renal adjustment required as systemic absorption is negligible.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, reduce dose by 50% and monitor for systemic effects.
No hepatic adjustment required as systemic absorption is negligible.
No specific Child-Pugh-based adjustments; caution in severe hepatic impairment due to reduced clearance; consider dose reduction of 50% in Child-Pugh Class C.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
0.15 mg/kg/dose (max 5 mg) via nebulization every 4-6 hours; or 1-2 inhalations (90 mcg each) via MDI every 4-6 hours as needed.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
Use lowest effective dose; potential for increased cardiovascular sensitivity; consider starting at 1.25 mg nebulization or 1 inhalation every 6 hours, titrate cautiously.
None
Increased risk of asthma-related death with beta-2 agonists; use inhaled beta-2 agonists alone for asthma is not recommended without concomitant inhaled corticosteroid.
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, arrhythmias), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and worsening of asthma symptoms.
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Hypersensitivity to beta-2 agonists or any component of the formulation; use in patients with tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular response) unless benefit outweighs risk.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
No significant food interactions. Avoid caffeine-containing foods and beverages if experiencing palpitations or tremors. Maintain adequate potassium intake as beta-2 agonists can cause hypokalemia.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemia, and intrauterine growth restriction due to beta-2 receptor stimulation. Prolonged use may delay labor.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
Excreted into breast milk in low amounts; M/P ratio estimated at 0.8 (range 0.5-1.2). Considered compatible with breastfeeding; monitor infant for signs of stimulation (e.g., tachycardia, irritability).
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
No routine dose adjustment required. Increased clearance in pregnancy may necessitate higher doses for bronchodilation; monitor clinical response. For tocolysis, use lowest effective dose and limit duration to 48-72 hours due to maternal-fetal risks.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Beta-2 agonists (e.g., albuterol, salmeterol) are primarily used for bronchodilation in asthma and COPD. Short-acting beta-2 agonists (SABAs) are first-line for acute symptoms, while long-acting beta-2 agonists (LABAs) are maintenance therapy, never as monotherapy in asthma. Monitor for hypokalemia and tachycardia. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Inhaled route minimizes systemic effects. Overuse indicates poor disease control.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
Use only as prescribed; do not increase frequency or dose without consulting your doctor.,Rinse mouth with water after using inhalers containing corticosteroids to prevent thrush.,Seek emergency help if symptoms worsen or if you need more than 2 puffs per week of rescue inhaler.,Know the difference between rescue (blue) and controller (usually brown/purple) inhalers.,Shake inhaler well before use and use proper technique (spacer if needed).,Report palpitations, chest pain, or severe anxiety to your healthcare provider.,Do not stop controller medication suddenly as it may cause worsening of symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETASOL HC vs BETA-2, answered by our medical review team.
ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. BETA-2 is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETASOL HC and BETA-2 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. The standard adult dose of BETA-2 is: 2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETASOL HC and BETA-2 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. BETA-2 is classified as Category C. FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.